Glycan masking of a non-neutralising epitope enhances neutralising antibodies targeting the RBD of SARS-CoV-2 and its variants

The accelerated development of the first generation COVID-19 vaccines has saved millions of lives, and potentially more from the long-term sequelae of SARS-CoV-2 infection. The most successful vaccine candidates have used the full-length SARS-CoV-2 spike protein as an immunogen. As expected of RNA v...

Celý popis

Podrobná bibliografie

Hlavní autoři:	George W. Carnell, Martina Billmeier, Sneha Vishwanath, Maria Suau Sans, Hannah Wein, Charlotte L. George, Patrick Neckermann, Joanne Marie M. Del Rosario, Alexander T. Sampson, Sebastian Einhauser, Ernest T. Aguinam, Matteo Ferrari, Paul Tonks, Angalee Nadesalingam, Anja Schütz, Chloe Qingzhou Huang, David A. Wells, Minna Paloniemi, Ingo Jordan, Diego Cantoni, David Peterhoff, Benedikt Asbach, Volker Sandig, Nigel Temperton, Rebecca Kinsley, Ralf Wagner, Jonathan L. Heeney
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Frontiers Media S.A. 2023-02-01
Edice:	Frontiers in Immunology
Témata:	SARS-CoV-2 antibody receptor binding domain (RBD) glycan masking neutralising antibodies pseudotype neutralisation
On-line přístup:	https://www.frontiersin.org/articles/10.3389/fimmu.2023.1118523/full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!